Literature DB >> 21707474

Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Victoria A Ploplis1.   

Abstract

Plasminogen Activator Inhibitor-1 (PAI-1) is a multifunctional protein with the ability to not only regulate fibrinolysis through inhibition of plasminogen activation, but also cell signaling events which have direct downstream effects on cell function. Elevated plasma levels of this protein have been shown to have profound effects on the development and progression of cardiovascular diseases. However, results from a number of studies, especially those using PAI-1 deficient mouse models, have demonstrated that its function is ambiguous, with evidence of both preventing and enhancing various disease states. A number of lifestyle changes and pharmacological reagents have been identified that can regulate PAI-1 levels or function. Those reagents that target function are focused on its ability to regulate plasmin formation, and have been studied in in vivo models of thrombosis. Further investigations involving regulation of cell function could potentially resolve paradoxical issues associated with the function of this protein in regulating cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707474      PMCID: PMC3674863          DOI: 10.2174/138945011797635803

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  110 in total

1.  TGF-beta1-induced cardiac myofibroblasts are nonproliferating functional cells carrying DNA damages.

Authors:  Victor V Petrov; Jos F van Pelt; Joris R Vermeesch; Viktor J Van Duppen; Katrien Vekemans; Robert H Fagard; Paul J Lijnen
Journal:  Exp Cell Res       Date:  2008-01-26       Impact factor: 3.905

2.  Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-beta1 from the extracellular matrix of growth plate chondrocytes.

Authors:  H A Pedrozo; Z Schwartz; M Robinson; R Gomes; D D Dean; L F Bonewald; B D Boyan
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

3.  A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells.

Authors:  Rashna D Balsara; Francis J Castellino; Victoria A Ploplis
Journal:  J Biol Chem       Date:  2006-06-19       Impact factor: 5.157

Review 4.  Hypertension and atherosclerosis.

Authors:  M Baudouin-Legros; P Meyer
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 5.  Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly.

Authors:  Koji Yamamoto; Kyosuke Takeshita; Tetsuhito Kojima; Junki Takamatsu; Hidehiko Saito
Journal:  Cardiovasc Res       Date:  2004-12-08       Impact factor: 10.787

6.  CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC.

Authors:  Youjun Chen; Ingrid E Blom; Susan Sa; Roel Goldschmeding; David J Abraham; Andrew Leask
Journal:  Kidney Int       Date:  2002-10       Impact factor: 10.612

7.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

Authors:  P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta.

Authors:  L E Odekon; F Blasi; D B Rifkin
Journal:  J Cell Physiol       Date:  1994-03       Impact factor: 6.384

9.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo.

Authors:  S E Crawford; V Stellmach; J E Murphy-Ullrich; S M Ribeiro; J Lawler; R O Hynes; G P Boivin; N Bouck
Journal:  Cell       Date:  1998-06-26       Impact factor: 41.582

10.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

View more
  18 in total

Review 1.  Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.

Authors:  Farzad Masoudkabir; Nizal Sarrafzadegan; Carolyn Gotay; Andrew Ignaszewski; Andrew D Krahn; Margot K Davis; Christopher Franco; Arya Mani
Journal:  Atherosclerosis       Date:  2017-06-02       Impact factor: 5.162

2.  PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.

Authors:  Monica Mariana Baluta; Marius Marcian Vintila
Journal:  Maedica (Buchar)       Date:  2015-06

3.  Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI).

Authors:  Cristina Puy; Anh T P Ngo; Jiaqing Pang; Ravi S Keshari; Matthew W Hagen; Monica T Hinds; David Gailani; András Gruber; Florea Lupu; Owen J T McCarty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-05-23       Impact factor: 8.311

4.  Associations of Serum 25-Hydroxyvitamin D With Hemostatic and Inflammatory Biomarkers in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Marc Blondon; Mary Cushman; Nancy Jenny; Erin D Michos; Nicholas L Smith; Bryan Kestenbaum; Ian H de Boer
Journal:  J Clin Endocrinol Metab       Date:  2016-03-29       Impact factor: 5.958

5.  Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.

Authors:  Tihami Qureshi; Sumit Goswami; Carlee S McClintock; Matthew T Ramsey; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-12-02       Impact factor: 6.725

Review 6.  Association of plasminogen activator inhibitor-1 4G5G Polymorphism with risk of diabetic nephropathy and retinopathy: a systematic review and meta-analysis.

Authors:  Seyed Alireza Dastgheib; Farzaneh Najafi; Ahmad Shajari; Reza Bahrami; Fatemeh Asadian; Jalal Sadeghizadeh-Yazdi; Elahe Akbarian; Seyed Alireza Emarati; Hossein Neamatzadeh
Journal:  J Diabetes Metab Disord       Date:  2020-11-03

7.  Chemical constituents of ambient particulate air pollution and biomarkers of inflammation, coagulation and homocysteine in healthy adults: a prospective panel study.

Authors:  Shaowei Wu; Furong Deng; Hongying Wei; Jing Huang; Hongyi Wang; Masayuki Shima; Xin Wang; Yu Qin; Chanjuan Zheng; Yu Hao; Xinbiao Guo
Journal:  Part Fibre Toxicol       Date:  2012-12-12       Impact factor: 9.400

8.  The -844 G>A PAI-1 polymorphism is associated with acute coronary syndrome in Mexican population.

Authors:  Ilian Janet García-González; Yeminia Valle; Elena Sandoval-Pinto; Emmanuel Valdés-Alvarado; Angélica Valdez-Haro; José Francisco Muñoz-Valle; Héctor Enrique Flores-Salinas; Luis Eduardo Figuera-Villanueva; Nory Omayra Dávalos-Rodríguez; Jorge Ramón Padilla-Gutiérrez
Journal:  Dis Markers       Date:  2015-02-19       Impact factor: 3.434

9.  Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.

Authors:  Tessa M Simone; Stephen P Higgins; Craig E Higgins; Michelle R Lennartz; Paul J Higgins
Journal:  J Mol Genet Med       Date:  2014-10

10.  The urea decomposition product cyanate promotes endothelial dysfunction.

Authors:  Dalia El-Gamal; Shailaja P Rao; Michael Holzer; Seth Hallström; Johannes Haybaeck; Martin Gauster; Christian Wadsack; Andrijana Kozina; Saša Frank; Rudolf Schicho; Rufina Schuligoi; Akos Heinemann; Gunther Marsche
Journal:  Kidney Int       Date:  2014-06-18       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.